Radiopharm Theranostics Limited RADX
Regular-session close
After hours · Nov 19, 4:00 PM ET
- YTD
- -87.11%
- 1 year
- -85.43%
5D -0.1200 (-15.79%)
- Market cap
- 10.57M
- Revenue (ttm)
- 1.96M
- EPS (ttm)
- -3.57
- YTD return
- -87.11%
- 1-year return
- -85.43%
- 50-day average
- 7.67
- 200-day average
- 7.67
- Volume
- 27.20K
- Avg volume
- 56.72K
- Open
- 0.6319
- Previous close
- 0.6851
- Day's range
- 0.6319 – 0.70
- 52-week range
- 0.671 – 10.63
- Beta
- 0.85
Key statistics
- Enterprise value
- 9.52B
- Price / book
- 69.02
- Free cash flow
- -12.04M
- Total cash
- 18.58M
- Return on equity
- -131.49%
Fundamental scorecard
3 of 25 checks passed on RADX’s reported financials
3of 25 checks passed
- Value 0 of 5
- Growth 0 of 5
- Profitability 1 of 5
- Financial health 2 of 5
- Dividend 0 of 5
Statements to Jun 30, 2026.
Financials — quick view
About Radiopharm Theranostics Limited
Radiopharm Theranostics Limited engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs. It develops RAD 204, a programmed death-ligand 1 (PD-L1) for the treatment of non-small cell lung cancer (NSCLC); RAD 202, a human epidermal growth factor receptor 2 (HER2) to treat breast cancer and other solid tumors; and RAD 301, a diagnostic radiopharmaceutical targeting avß6 integrin in pancreatic ductal adenocarcinoma patients. The company also develops RAD 302, an avß6-integrin targeting agent for the treatment of multiple cancer types; RAD 101 and RAD 102 for brain metastases; RAD 402 to treat advanced prostate cancer; and RV01 for multiple solid tumors. The company was incorporated in 2021 and is based in Carlton, Australia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Australia
- Website
- radiopharmtheranostics.com
News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Radiopharm Theranostics Announces Alignment with U.S. FDA on Single Pivotal Phase 3 Trial for RAD101 in Diagnosis of Brain Metastases
Radiopharm Theranostics Reports Business Update
12 Health Care Stocks Moving In Friday's After-Market Session
Radiopharm Theranostics Announces Positive Data from the Phase 1 Imaging Trial of RAD301 in Patients with Pancreatic Ductal Adenocarcinoma
Radiopharm Theranostics Doses First Patient in Second Cohort of Phase 1/2a Clinical Trial of BetaBart (RV-01) in B7-H3 Expressing Solid Tumors
Radiopharm Theranostics (NASDAQ:RADX) Trading Down 8.4% – What’s Next?
Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Clinical Trial
Radiopharm Theranostics Announces Concurrent US$4.1 Million Registered Direct Offering and Up To Additional A$12.7 (US$8.9) Million Australian Placement and Share Purchase Plan
Radiopharm Theranostics Achieves Confirmed Durable Partial Response in Ongoing Phase 1 Trial of RAD204 in Patients with Advanced Solid Tumors Post-Immunotherapy
Your note
Sign in to keep a note on RADX — it syncs with the Stock Master app.
